CircRNA_001569 promotes cell proliferation through absorbing miR-145 in gastric cancer.


Journal

Journal of biochemistry
ISSN: 1756-2651
Titre abrégé: J Biochem
Pays: England
ID NLM: 0376600

Informations de publication

Date de publication:
01 Jan 2019
Historique:
received: 27 06 2018
accepted: 08 10 2018
pubmed: 12 10 2018
medline: 25 1 2019
entrez: 11 10 2018
Statut: ppublish

Résumé

Gastric cancer severely threatens human life, while its pathogenesis is still unclear. The present study was to explore the potential pathogenic mechanism underlying gastric cancer. Real-time PCR was performed to detect the expression of circRNA_001569 and miR-145; western blot was performed to detect the expression of NR4A2. Cell cycle and apoptosis was determined using flow cytometry, and cell viability was determined using Cell counting kit-8 (CCK-8) assay. Luciferase reporter assay was carried out to validate the relationship between miR-145 and NR4A2. Both circRNA_001569 and NR4A2 were overexpressed in tissues and cells of gastric cancer, while miR-145 was down-regulated. Overexpressed circRNA_001569 significantly increased cell viability, and decreased cell apoptosis, while down-regulated circRNA_001569 dramatically decreased cell viability and promoted cell apoptosis. CircRNA_001569 regulated the expression of miR-145, the effect of pcDNA-circRNA_001569 was abolished by miR-145 mimic and the effect of si-circRNA_001569 was abolished by miR-145 inhibitor. MiR-145 targets NR4A2 to regulate its expression. Overexpressed miR-145 suppressed cell viability and promoted cell apoptosis. Taken together, the present study indicated that overexpressed circRNA_001569 promoted cell viability of gastric cancer through suppressing the expression of miR-145, which was mediated by NR4A2. The research will provide great theoretical basis for further clinical diagnosis and therapy.

Identifiants

pubmed: 30304349
pii: 5124291
doi: 10.1093/jb/mvy079
doi:

Substances chimiques

MIRN145 microRNA, human 0
MicroRNAs 0
NR4A2 protein, human 0
Nuclear Receptor Subfamily 4, Group A, Member 2 0
RNA, Circular 0
RNA 63231-63-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-36

Auteurs

Fengqian Shen (F)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Peijie Liu (P)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Zhiqiao Xu (Z)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Ning Li (N)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Zhenying Yi (Z)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Xiaojing Tie (X)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Yan Zhang (Y)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Ling Gao (L)

Department of Oncology, Kaifeng Central Hospital, Kaifeng, Henan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH